Which has stronger valuation & earnings, CNTX or TARA?

Protara Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is CNTX or TARA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Protara Therapeutics N/A -38.70% -36.02%

Does the media prefer CNTX or TARA?

In the previous week, Context Therapeutics had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Context Therapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.54 beat Context Therapeutics' score of 0.89 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, CNTX or SGMT?

Sagimet Biosciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Sagimet Biosciences N/A N/A -$51.04M -$1.34 N/A

Is CNTX or SGMT more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Sagimet Biosciences N/A -37.57% -35.52%

Does the media favor CNTX or SGMT?

In the previous week, Context Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Context Therapeutics and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.82 beat Context Therapeutics' score of 0.89 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, CNTX or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is CNTX or GLSI more profitable?

Context Therapeutics' return on equity of -59.95% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media favor CNTX or GLSI?

In the previous week, Greenwich LifeSciences had 15 more articles in the media than Context Therapeutics. MarketBeat recorded 19 mentions for Greenwich LifeSciences and 4 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.89 beat Greenwich LifeSciences' score of 0.77 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer CNTX or CHRS?

In the previous week, Context Therapeutics and Context Therapeutics both had 4 articles in the media. Coherus Oncology's average media sentiment score of 0.96 beat Context Therapeutics' score of 0.89 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or CNTX more profitable?

Oncobiologics' return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Context Therapeutics N/A -59.95% -54.78%

Does the media refer more to OTLK or CNTX?

In the previous week, Oncobiologics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 7 mentions for Oncobiologics and 4 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.89 beat Oncobiologics' score of 0.31 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Context Therapeutics (CNTX) Competitors

$0.61 +0.02 (+3.68%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.60 -0.01 (-1.97%)

As of 07/24/2026 07:20 PM Eastern

Compare

CNTX vs. TARA, SGMT, GLSI, CHRS, and OTLK

Should you buy Context Therapeutics stock or one of its competitors? MarketBeat compares Context Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Context Therapeutics include Protara Therapeutics (TARA), Sagimet Biosciences (SGMT), Greenwich LifeSciences (GLSI), Coherus Oncology (CHRS), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry.

How does Context Therapeutics compare to Protara Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Context Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Protara Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Protara Therapeutics' return on equity of -38.70% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Protara Therapeutics	N/A	-38.70%	-36.02%

Context Therapeutics currently has a consensus price target of $6.17, indicating a potential upside of 904.18%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 552.99%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Context Therapeutics is more favorable than Protara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Context Therapeutics had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Context Therapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.54 beat Context Therapeutics' score of 0.89 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Context Therapeutics beats Protara Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Context Therapeutics compare to Sagimet Biosciences?

Context Therapeutics (NASDAQ:CNTX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 904.18%. Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 261.69%. Given Context Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Context Therapeutics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Sagimet Biosciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Sagimet Biosciences	N/A	N/A	-$51.04M	-$1.34	N/A

Context Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.35, suggesting that its share price is 235% more volatile than the broader market.

Sagimet Biosciences' return on equity of -37.57% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Sagimet Biosciences	N/A	-37.57%	-35.52%

In the previous week, Context Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Context Therapeutics and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.82 beat Context Therapeutics' score of 0.89 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Context Therapeutics and Sagimet Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Greenwich LifeSciences?

Context Therapeutics (NASDAQ:CNTX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Context Therapeutics' return on equity of -59.95% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Context Therapeutics currently has a consensus price target of $6.17, suggesting a potential upside of 904.18%. Greenwich LifeSciences has a consensus price target of $57.00, suggesting a potential upside of 339.14%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Greenwich LifeSciences had 15 more articles in the media than Context Therapeutics. MarketBeat recorded 19 mentions for Greenwich LifeSciences and 4 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.89 beat Greenwich LifeSciences' score of 0.77 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Summary

Context Therapeutics beats Greenwich LifeSciences on 11 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Coherus Oncology?

Context Therapeutics (NASDAQ:CNTX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

In the previous week, Context Therapeutics and Context Therapeutics both had 4 articles in the media. Coherus Oncology's average media sentiment score of 0.96 beat Context Therapeutics' score of 0.89 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Coherus Oncology	$46.88M	4.64	$168.02M	$1.67	0.84

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Context Therapeutics currently has a consensus target price of $6.17, indicating a potential upside of 904.18%. Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 514.66%. Given Context Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Context Therapeutics is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has a net margin of 397.30% compared to Context Therapeutics' net margin of 0.00%. Context Therapeutics' return on equity of -59.95% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Coherus Oncology	397.30%	-198.90%	-46.65%

Summary

Coherus Oncology beats Context Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Context Therapeutics compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Oncobiologics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Context Therapeutics	N/A	-59.95%	-54.78%

In the previous week, Oncobiologics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 7 mentions for Oncobiologics and 4 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.89 beat Oncobiologics' score of 0.31 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Oncobiologics presently has a consensus price target of $6.50, indicating a potential upside of 362.63%. Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 904.18%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Context Therapeutics has lower revenue, but higher earnings than Oncobiologics. Context Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$333.14K	626.66	-$62.42M	-$1.17	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Summary

Context Therapeutics beats Oncobiologics on 11 of the 15 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.42M	$3.06B	$6.86B	$12.25B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-1.46	20.29	27.14	23.64
Price / Sales	N/A	485.21	517.01	89.03
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.93	4.13	10.28	6.07
Net Income	-$36.12M	$65.94M	$3.60B	$331.99M
7 Day Performance	2.35%	-4.16%	-1.27%	-0.63%
1 Month Performance	9.66%	-3.76%	-0.37%	-2.00%
1 Year Performance	-26.98%	9.94%	18.30%	13.62%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	2.5943 of 5 stars	$0.61 +3.7%	$6.17 +904.2%	-27.0%	$56.42M	N/A	N/A	7	Short Interest Increase Gap Up
TARA Protara Therapeutics	2.843 of 5 stars	$4.10 +0.6%	$26.25 +541.0%	+20.4%	$230.14M	N/A	N/A	30	News Coverage Upcoming Earnings
SGMT Sagimet Biosciences	3.1943 of 5 stars	$7.04 -1.7%	$25.57 +263.2%	-30.7%	$229.36M	$2M	N/A	8	News Coverage Positive News
GLSI Greenwich LifeSciences	1.9036 of 5 stars	$15.25 +8.4%	$57.00 +273.9%	+13.0%	$223.90M	N/A	N/A	3	News Coverage Positive News Analyst Forecast Analyst Revision
CHRS Coherus Oncology	3.5738 of 5 stars	$1.43 +0.7%	$8.67 +506.1%	+38.2%	$220.42M	$42.17M	0.86	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. TARA, SGMT, GLSI, CHRS, and OTLK

How does Context Therapeutics compare to Protara Therapeutics?

Summary

How does Context Therapeutics compare to Sagimet Biosciences?

Summary

How does Context Therapeutics compare to Greenwich LifeSciences?

Summary

How does Context Therapeutics compare to Coherus Oncology?

Summary

How does Context Therapeutics compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. TARA, SGMT, GLSI, CHRS, and OTLK

How does Context Therapeutics compare to Protara Therapeutics?

Which has more volatility and risk, CNTX or TARA?

Which has stronger valuation & earnings, CNTX or TARA?

Is CNTX or TARA more profitable?

Do analysts recommend CNTX or TARA?

Does the media prefer CNTX or TARA?

Do institutionals and insiders believe in CNTX or TARA?

Summary

How does Context Therapeutics compare to Sagimet Biosciences?

Do institutionals & insiders hold more shares of CNTX or SGMT?

Do analysts rate CNTX or SGMT?

Which has preferable valuation and earnings, CNTX or SGMT?

Which has more volatility and risk, CNTX or SGMT?

Is CNTX or SGMT more profitable?

Does the media favor CNTX or SGMT?

Summary

How does Context Therapeutics compare to Greenwich LifeSciences?

Is CNTX or GLSI more profitable?

Do analysts rate CNTX or GLSI?

Do institutionals and insiders hold more shares of CNTX or GLSI?

Does the media favor CNTX or GLSI?

Which has stronger valuation & earnings, CNTX or GLSI?

Which has more risk & volatility, CNTX or GLSI?

Summary

How does Context Therapeutics compare to Coherus Oncology?

Does the media prefer CNTX or CHRS?

Which has more volatility & risk, CNTX or CHRS?

Which has preferable earnings and valuation, CNTX or CHRS?

Do insiders and institutionals believe in CNTX or CHRS?

Do analysts rate CNTX or CHRS?

Is CNTX or CHRS more profitable?

Summary

How does Context Therapeutics compare to Oncobiologics?

Is OTLK or CNTX more profitable?

Does the media refer more to OTLK or CNTX?

Which has more risk and volatility, OTLK or CNTX?

Do analysts rate OTLK or CNTX?

Do institutionals & insiders have more ownership in OTLK or CNTX?

Which has better earnings & valuation, OTLK or CNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools